Multicenter study on the clinical usefulness of a new method diagnosing earlier development of pancreatic fibrosis, which targets proteolytic TGF-B-activation reaction.
- Conditions
- Chronic pancreatitis
- Registration Number
- JPRN-UMIN000007271
- Lead Sponsor
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Not provided
1.Patients with infections, difficult to control, for examples active tuberculosis. 2.Patients with severe drug allergy. 3.Patients with difficulty in the performance of endoscopy. 4.Patients with malignancy. 5.Patients with history of anticancer drug. 6.Patients with possible causes developing hepatic fibrosis without alcohol consumption, such as, viral hepatitis, autoimmune hepatitis,non-alcoholic steatohepatitis, and CBD stones etc. 7.Patients with two times or more of the level of normal alanine transaminase (ALT). 8.Patients with interstitial pneumoniae and lung fibrosis. 9.Patients with severe complications. 10.Patients with pregnancy, lactating, possibility of pregnancy, or will of pregnancy. 11.Patients with severe mental disorder.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study whether the level of TGF-B LAP-D correlates with the stage of chronic pancreatitis.
- Secondary Outcome Measures
Name Time Method